XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

Background: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy. Therefore, the development of alternative synthetic lethality strategy, including in sporadic TNBC, is a priority. XRCC1, a key player in base excision repair, single strand break repair, nucleotide excision repair and alternative non-homologous end joining, interacts with PARP1 and coordinates DNA repair. ATR, ATM and Wee1 have essential roles in DNA repair and cell cycle regulation. Methods: Highly selective inhibitors of ATR (AZD6738), ATM (AZ31) and Wee1 (AZD1775) either alone or in combination with olaparib were tested for synthetic lethality in XRCC1 deficient TNBC or HeLa cells. Clinicopathological significance of ATR, ATM or Wee1 co-expression in XRCC1 proficient or deficient tumours was evaluated in a large cohort of 1650 human breast cancers. Results: ATR (AZD6738), ATM (AZ31) or Wee1 (AZD1775) monotherapy was selectively toxic in XRCC1 deficient cells. Selective synergistic toxicity was evident when olaparib was combined with AZD6738, AZ31 or AZD1775. The most potent synergistic interaction was evident with the AZD6738 and olaparib combination therapy. In clinical cohorts, ATR, ATM or Wee1 overexpression in XRCC1 deficient breast cancer was associated with poor outcomes. Conclusion: XRCC1 stratified DNA repair targeted combinatorial approach is feasible and warrants further clinical evaluation in breast cancer.

[1]  K. Caldecott.  XRCC1 protein; Form and function. , 2019, DNA repair.

[2]  G. Mills,et al.  Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. , 2019, Cancer cell.

[3]  A. D’Andrea.  Mechanisms of PARP inhibitor sensitivity and resistance. , 2018, DNA repair.

[4]  J. Nissink,et al.  Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. , 2018, Journal of medicinal chemistry.

[5]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[6]  A. Green,et al.  Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention. , 2018, Cancer research.

[7]  K. Keyomarsi,et al.  Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy , 2018, Expert opinion on investigational drugs.

[8]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[9]  Juanita Lopez,et al.  Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies , 2018, Therapeutic advances in medical oncology.

[10]  A. Jeyasekharan,et al.  Biomarkers for Homologous Recombination Deficiency in Cancer , 2018, Journal of the National Cancer Institute.

[11]  L. Shen,et al.  Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint , 2018, Journal of experimental & clinical cancer research : CR.

[12]  Crispin J. Miller,et al.  The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer , 2018, Clinical Cancer Research.

[13]  A. Lau,et al.  The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression , 2018, Molecular Cancer Therapeutics.

[14]  K. Harrington,et al.  PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours , 2018, Clinical and translational radiation oncology.

[15]  I. Barrett,et al.  The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models , 2018, Science Advances.

[16]  K. Thiel,et al.  AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations , 2018, Cancers.

[17]  Zhu Yuan,et al.  ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN‐deficient breast cancer cells to cisplatin , 2018, Experimental cell research.

[18]  Fang Yang,et al.  Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer , 2018, Neoplasia.

[19]  Arnaud J. Legrand,et al.  Sp1 phosphorylation by ATM downregulates BER and promotes cell elimination in response to persistent DNA damage , 2017, Nucleic acids research.

[20]  T. Pitts,et al.  The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy , 2017, Oncotarget.

[21]  S. Fosmire,et al.  A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia , 2017, Molecular Cancer Therapeutics.

[22]  S. Jackson,et al.  ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. , 2017, Molecular cell.

[23]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[24]  C. Deng,et al.  WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance , 2017, Scientific Reports.

[25]  Y. Bang,et al.  AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells , 2017, Molecular Cancer Therapeutics.

[26]  Anne Floquet,et al.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[27]  Y. Bang,et al.  Anti‐tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells , 2017, International journal of cancer.

[28]  Samuel E. Jones,et al.  ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A , 2016, Nature Communications.

[29]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[30]  D. Backos,et al.  Targeting WEE1 Kinase in Cancer. , 2016, Trends in pharmacological sciences.

[31]  T. Stankovic,et al.  ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. , 2016, Blood.

[32]  T. Conrads,et al.  The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo , 2015, Oncotarget.

[33]  J. Doroshow,et al.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Graham Ball,et al.  Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer , 2015, Molecular oncology.

[35]  Jer-Tsong Hsieh,et al.  The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect , 2015, International journal of radiation biology.

[36]  G. Ball,et al.  Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy , 2015, Molecular oncology.

[37]  G. Ball,et al.  Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts , 2014, Neoplasia.

[38]  Jin-hai Tang,et al.  Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer , 2014, Oncology letters.

[39]  Graham Ball,et al.  Targeting XRCC1 deficiency in breast cancer for personalized therapy. , 2013, Cancer research.

[40]  C. Seedhouse,et al.  Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells , 2013, PloS one.

[41]  R. Muschel,et al.  The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy , 2012, Cancer biology & therapy.

[42]  P. Reaper,et al.  Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.

[43]  E. Rosen,et al.  Transcriptional Regulation of the Base Excision Repair Pathway by BRCA1* , 2010, The Journal of Biological Chemistry.

[44]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[45]  Mariela C. Marazita,et al.  E2F1 transcription is induced by genotoxic stress through ATM/ATR activation , 2009, IUBMB life.

[46]  E. Alli,et al.  Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. , 2009, Cancer research.

[47]  C. Lopez,et al.  E2F1 Regulates the Base Excision Repair Gene XRCC1 and Promotes DNA Repair* , 2008, Journal of Biological Chemistry.

[48]  J. Nevins,et al.  Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. , 2001, Genes & development.